Dabigatran
Cross-source consensus on Dabigatran from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Benefits
Dosage & preparation
Highlighted claims
- The trial dabigatran dose is 150 mg orally twice daily, with a 110 mg twice-daily option for selected older or higher-bleeding-risk patients where available. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
- Dabigatran is approved for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of DVT and pulmonary embolism. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
- Dabigatran inhibits bacterial coagulase and staphylothrombin-mediated fibrin deposition. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
- Animal models found dabigatran reduced S. aureus abscess size and endocarditis measures. — Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial